Clinical Autonomic Research 2008-03-01

L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.

Horacio Kaufmann

Index: Clin. Auton. Res. 18 Suppl 1 , 19-24, (2008)

Full Text: HTML

Abstract

Neurogenic orthostatic hypotension results from failure to release norepinephrine, the neurotransmitter of sympathetic postganglionic neurons, appropriately upon standing. In double blind, cross over, placebo controlled trials, administration of droxidopa, a synthetic amino acid that is decarboxylated to norepinephrine by the enzyme L: -aromatic amino acid decarboxylase increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability in patients with neurogenic orthostatic hypotension due to degenerative autonomic disorders. The pressor effect results from conversion of droxidopa to norepinephrine outside the central nervous system both in neural and non-neural tissue. This mechanism of action makes droxidopa effective in patients with central and peripheral autonomic disorders.

Related Compounds

  • droxidopa

Related Articles:

Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations.

2014-11-20

[Eur. J. Pharm. Sci. 64 , 37-43, (2014)]

[Acute poisoning of droxidopa: report of a case].

2013-09-01

[Chudoku. Kenkyu. 26(3) , 244-5, (2013)]

The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

2012-01-01

[Neurobiol. Aging 33(8) , 1651-63, (2012)]

Comment on "Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension" by Fujisaki et al.

2007-10-01

[Ther. Apher. Dial. 11(5) , 407-8, (2007)]

Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.

2015-01-01

[Hypertension 65(1) , 101-7, (2015)]

More Articles...